NEKTAR THERAPEUTICS's ticker is NKTR and the CUSIP is 640268108. A total of 216 filers reported holding NEKTAR THERAPEUTICS in Q4 2022. The put-call ratio across all filers is 0.90 and the average weighting 0.0%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q2 2024 | $8 | -84.6% | 6,177 | -91.6% | 0.00% | – |
Q1 2023 | $52 | -70.8% | 73,886 | -6.0% | 0.00% | -100.0% |
Q4 2022 | $178 | -99.9% | 78,586 | -5.5% | 0.00% | -33.3% |
Q3 2022 | $266,000 | -12.8% | 83,139 | +3.6% | 0.00% | 0.0% |
Q2 2022 | $305,000 | -33.0% | 80,230 | -5.0% | 0.00% | -25.0% |
Q1 2022 | $455,000 | -71.6% | 84,491 | -28.7% | 0.00% | -33.3% |
Q4 2021 | $1,600,000 | -31.3% | 118,484 | -8.6% | 0.01% | -70.0% |
Q3 2021 | $2,329,000 | -4.8% | 129,667 | -9.0% | 0.02% | 0.0% |
Q2 2021 | $2,446,000 | +463.6% | 142,543 | +557.1% | 0.02% | +25.0% |
Q1 2021 | $434,000 | +10.4% | 21,693 | -6.1% | 0.02% | +6.7% |
Q4 2020 | $393,000 | +2.9% | 23,113 | +0.4% | 0.02% | -11.8% |
Q3 2020 | $382,000 | -28.7% | 23,032 | -0.5% | 0.02% | -32.0% |
Q2 2020 | $536,000 | -22.9% | 23,143 | -40.6% | 0.02% | +47.1% |
Q1 2020 | $695,000 | -18.7% | 38,952 | -1.7% | 0.02% | +6.2% |
Q4 2019 | $855,000 | +27.0% | 39,608 | +7.1% | 0.02% | +14.3% |
Q3 2019 | $673,000 | -48.2% | 36,966 | +1.4% | 0.01% | -53.3% |
Q2 2019 | $1,298,000 | +64.3% | 36,469 | +55.2% | 0.03% | +57.9% |
Q1 2019 | $790,000 | +4.4% | 23,498 | +2.0% | 0.02% | -9.5% |
Q4 2018 | $757,000 | -47.5% | 23,036 | -2.7% | 0.02% | -41.7% |
Q3 2018 | $1,443,000 | +21.0% | 23,677 | -3.1% | 0.04% | +24.1% |
Q2 2018 | $1,193,000 | -50.3% | 24,427 | +8.0% | 0.03% | -54.7% |
Q1 2018 | $2,402,000 | +84.8% | 22,609 | +3.8% | 0.06% | +82.9% |
Q4 2017 | $1,300,000 | +164.8% | 21,775 | +6.3% | 0.04% | +133.3% |
Q3 2017 | $491,000 | +22.1% | 20,477 | -0.4% | 0.02% | +15.4% |
Q2 2017 | $402,000 | -9.5% | 20,563 | +8.7% | 0.01% | -40.9% |
Q1 2017 | $444,000 | +91.4% | 18,919 | -0.1% | 0.02% | +120.0% |
Q4 2016 | $232,000 | -10.1% | 18,939 | +26.1% | 0.01% | -33.3% |
Q3 2016 | $258,000 | 0.0% | 15,019 | -0.0% | 0.02% | 0.0% |
Q2 2016 | $258,000 | +35.8% | 15,020 | +8.5% | 0.02% | -21.1% |
Q1 2016 | $190,000 | -10.8% | 13,843 | +9.8% | 0.02% | -26.9% |
Q4 2015 | $213,000 | +40.1% | 12,612 | -8.9% | 0.03% | +62.5% |
Q3 2015 | $152,000 | -10.6% | 13,842 | +1.7% | 0.02% | -5.9% |
Q2 2015 | $170,000 | – | 13,608 | – | 0.02% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Rhenman & Partners Asset Management AB | 1,350,000 | $22,950,000 | 1.87% |
MAVERICK CAPITAL LTD | 6,655,625 | $113,146,000 | 1.81% |
Camber Capital Management LP | 2,500,000 | $42,500,000 | 1.49% |
Bellevue Group AG | 3,866,258 | $65,726,000 | 0.75% |
Adero Partners, LLC | 51,500 | $876,000 | 0.75% |
Goodman Financial Corp | 108,342 | $1,842,000 | 0.64% |
CM Management, LLC | 35,000 | $595,000 | 0.55% |
OSTERWEIS CAPITAL MANAGEMENT INC | 424,504 | $7,217,000 | 0.43% |
RICE HALL JAMES & ASSOCIATES, LLC | 568,379 | $9,662,000 | 0.34% |
Burleson & Company, LLC | 107,736 | $1,832,000 | 0.32% |